Valuation: Autolus Therapeutics plc

Market Cap 500M 434M 409M 371M 696M 47.96B 701M 4.89B 1.88B 24.33B 1.88B 1.84B 77.35B P/E 2026 *
-2.34x
P/E 2027 * -2.76x
Enterprise Value 344M 298M 282M 255M 479M 33.01B 483M 3.36B 1.3B 16.74B 1.29B 1.26B 53.23B EV / Sales 2026 *
2.3x
EV / Sales 2027 * 2.2x
Free-Float
-
Yield 2026 *
-
Yield 2027 * -
1 day+3.19%
1 week-8.06%
Current month-17.45%
1 month-9.77%
3 months+29.33%
6 months+28.48%
Current year-2.51%
1 week 1.85
Extreme 1.85
2.23
1 month 1.85
Extreme 1.85
2.58
Current year 1.18
Extreme 1.175
2.58
1 year 1.18
Extreme 1.175
2.58
3 years 1.1
Extreme 1.105
7.45
5 years 1.1
Extreme 1.105
7.9
10 years 1.1
Extreme 1.105
53.24
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer 53 2014-08-31
Chief Executive Officer 61 2016-02-29
Director of Finance/CFO 56 2023-08-06
Director TitleAgeSince
Chairman 61 2014-09-30
Director/Board Member 78 2014-07-31
Director/Board Member 71 2018-02-28
Date Insider Type Main position Quantity % Market Cap. Importance
9/2/26 Sell

Executive/Senior Manager

-6,713 0.0025%
6/29/26 Free

Director

79,167 0.0477%
3/18/26 Other

Chief Executive Officer

6,917,877 4.1641%
Change 5-day change 1-year change 3-year change Capi.($)
+3.19%-8.06%+46.97%-32.87% 500M
+1.57%-2.04%+38.62%-4.64% 78.04B
+1.89%+4.53%+514.28%+30.03% 57.48B
+2.68%-1.68%-17.44%-36.27% 57.4B
+0.35%-1.87%-11.03%+27.74% 48.81B
+2.38%-0.05%+1.49%+157.52% 45.5B
+0.10%+2.29%+51.66%-15.20% 32.08B
+0.59%-1.78%+46.97%+92.49% 24.62B
+3.53%-5.42%-1.02%+170.53% 20.77B
+2.24%-1.45%+66.12%+103.91% 15.75B
Average +1.84%-4.88%+73.66%+49.32% 38.09B
Weighted average by Cap. +1.65%-3.46%+91.77%+38.73%

Financials

2026 *2027 *
Net sales 150M 130M 122M 111M 208M 14.36B 210M 1.46B 564M 7.28B 563M 550M 23.15B 192M 167M 157M 143M 268M 18.44B 270M 1.88B 724M 9.36B 723M 707M 29.74B
Net income -219M -190M -179M -162M -305M -20.98B -307M -2.14B -824M -10.64B -822M -804M -33.83B -185M -161M -152M -138M -258M -17.77B -260M -1.81B -698M -9.01B -696M -681M -28.66B
Net Debt -156M -135M -128M -116M -217M -14.95B -219M -1.52B -587M -7.59B -586M -573M -24.12B -77.38M -67.05M -63.27M -57.4M -108M -7.42B -108M -756M -291M -3.76B -291M -284M -11.96B
Logo Autolus Therapeutics plc
Autolus Therapeutics plc is a United Kingdom-based early commercial-stage biopharmaceutical company developing programmed T cell therapies for the treatment of cancer and autoimmune diseases. The Company has an approved commercial product, AUCATZYL, for the treatment of adult patients with r/r B-ALL. Using a suite of proprietary and modular T cell programming technologies, it is also developing five programs in seven hematological and solid tumor indications and one autoimmune indication. It is engineering precisely targeted, controlled and highly active T cell therapies that are designed to better recognize target cells, break down their defense mechanisms and attack and eliminate these cells. Its product pipeline includes obe-cel (ALLCAR19), obe-cel (CAROUSEL), AUTO1/22 (CARPALL), AUTO4 (LibrA T1), AUTO6 (MAGNETO), AUTO5, AUTO8 (MCARTY) and AUTO9. AUTO4 and AUTO5 are two programmed T cell therapies for the treatment of peripheral T-cell lymphoma targeting TRBC 1 and TRBC 2.
Employees
753
Date Price Change Volume
26-09-14 $1.940 +3.19% 1,479,914
26-09-11 $1.880 -4.08% 1,724,835
26-09-10 $1.960 -3.45% 1,328,065
26-09-09 $2.030 -3.79% 1,715,650
26-09-08 $2.110 -5.80% 2,568,363
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
1.880USD
Average target price
8.725USD
Spread / Average Target
+364.10%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. AUTL Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!